Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Leases (2022 - 2026)

Indivior Pharmaceuticals has reported Leases over the past 5 years, most recently at $22.0 million for Q1 2026.

  • For Q1 2026, Leases fell 40.54% year-over-year to $22.0 million; the TTM value through Mar 2026 reached $22.0 million, down 40.54%, while the annual FY2025 figure was $26.0 million, 33.33% down from the prior year.
  • Leases for Q1 2026 was $22.0 million at Indivior Pharmaceuticals, down from $26.0 million in the prior quarter.
  • Over five years, Leases peaked at $40.0 million in Q4 2023 and troughed at $22.0 million in Q1 2026.
  • A 5-year average of $32.9 million and a median of $33.0 million in 2024 define the central range for Leases.
  • Biggest five-year swings in Leases: increased 29.03% in 2023 and later tumbled 40.54% in 2026.
  • Year by year, Leases stood at $31.0 million in 2022, then rose by 29.03% to $40.0 million in 2023, then dropped by 2.5% to $39.0 million in 2024, then crashed by 33.33% to $26.0 million in 2025, then decreased by 15.38% to $22.0 million in 2026.
  • Business Quant data shows Leases for INDV at $22.0 million in Q1 2026, $26.0 million in Q4 2025, and $30.0 million in Q3 2025.